www.psychiatriepropraxi.cz / Psychiatr. praxi. 2025;26(2):75-82 / PSYCHIATRIE PRO PRAXI 81 PŘEHLEDOVÉ ČLÁNKY Generalizovaná úzkostná porucha a její léčba je psychosociální fungování jedince. Diagnostika a stanovení závažnosti příznaků se opírá o standardizované nástroje, jako je 7položková škála GAD-7 a Hamiltonova škála úzkosti (HAM-A). Léčba GAD zahrnuje: Farmakoterapii: první volbou jsou SSRI a SNRI, nadějné v léčbě se ukazují také pregabalin, agomelatin nebo vortioxetin. Psychoterapii: kognitivně-behaviorální terapie (KBT) je považována za nejefektivnější, s možností využití technik jako mindfulness a expoziční terapie, aplikovatelné také ve virtuální realitě. Neinvazivní stimulační metody: repetitivní transkraniální magnetická stimulace (rTMS) se ukazuje jako účinná, zatímco tDCS pravděpodobně efektivní není. Celkově je léčba GAD komplexní a vyžaduje individualizovaný přístup. Digitální intervence mohou být užitečnou alternativou, zejména v případě omezeného přístupu k tradičním terapiím. Využití virtuální reality má hlavní přínos v oblasti expoziční terapie a umožňuje personalizovaný a interaktivní přístup v léčbě GAD. LITERATURA 1. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. 2019; 393(10173):768777. doi.org/10.1016/S0140–6736(18)31793-8. 2. Gottschalk MG, Domschke K. Genetics of generalized anxiety disorder and related traits. Dialogues in Clinical Neuroscience. 2017;19(2):159-168. 3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. 4. Bandelow B, Boerner JR, Kasper S, et al. The diagnosis and treatment of generalized anxiety disorder. Deutsches Arzteblatt international. 2013;110(17):300-310. doi.org/10.3238/ arztebl.2013.0300. 5. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). Geneva: WHO. 1992. 6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: APA. 1994. 7. Hofmann SG, Asnaani A, Vonk IJJ, et al. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognitive Therapy and Research. 2012;36(5):427-440. 8. World Health Organization. International Classification of Diseases 11th Revision (ICD-11). ICD-11. 2019. 9. Spitzer RL, Kroenke K, Williams JBW, et al. Brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine. 2006;166(10):1092-1097. doi.org/10.1001/ archinte.166. 10. 1092; do českého jazyka zpracováno leden 2012. RBTLYR-11–236. 10. Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders. 1988;14(1):61-68. doi.org/10.1016/0165– 0327(88)90072–9. 11. Nosková E, Šebela A, Stopková P. Aktuální trendy v léčbě generalizované úzkostné poruchy. Psychiatr. praxi. 2020;21(2):66-72. 12. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta‑analysis. 2019. The Lancet. 393(10173):768-777. doi.org/10.1016/S0140–6736(18)31793–8. 13. Guaiana G, Barbui C, Churchill R, et al. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews. 2007(4). doi.org/10.1002/14651858.CD006815 14. Strawn JR, Geracioti TD Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat. 2007 Apr;3(2):237-43. doi: 10.2147/ nedt.2007. 3. 2.237. PMID: 19300556; PMCID: PMC2654629. 15. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003 Mar;160(3):533-40. doi: 10.1176/appi. ajp.160. 3. 533. PMID: 12611835. 16. Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017 Jan;32(1):4955. doi: 10.1097/YIC.0000000000000147. PMID: 27643884. 17. Schjerning O, Rosenzweig M, Pottegård A, et al. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs. 2016 Jan;30(1):9-25. doi: 10.1007/s40263-015-0303-6. PMID: 26767525. 18. Buoli M, Grassi S, Serati M, et al. Agomelatine for the treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy. 2017;18(13):1373–1379. https://doi.org/1 0.1080/14656566.2017.1359257. 19. Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence‑based treatment review. Expert Opinion on Pharmacotherapy. 2018;19(10):1057–1070. doi.or g/10.108 0/14656566.2018.1491966. 20. Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: A systematic review and meta‑analysis of randomized controlled trials. Drug Design, Development and Therapy. 2016; 10:259-276. 21. Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007 Feb 1;356(5):479-85. doi: 10.1056/NEJMoa064725. PMID: 17267908. 22. Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double‑blind, randomised, placebo‑controlled study. Australian and New Zealand Journal of Psychiatry. 2020;54(3):288-297. https://doi. org/10.1177/0004867419891246. 23. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023 Feb;24(2):79-117. doi: 10.1080/15622975.2022.2086295. Epub 2022 Jul 28. PMID: 35900161. 24. Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020 Dec 23;11:595584. doi: 10.3389/ fpsyt.2020.595584. PMID: 33424664; PMCID: PMC7786299. 25. Christensen MC, Schmidt S, Grande I. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. J Psychopharmacol. 2022 May;36(5):566-577. doi: 10.1177/02698811221090627. Epub 2022 May 2. PMID: 35499104; PMCID: PMC9112621. 26. Feulner L, Sermchaiwong T, Rodland N, et al. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders. Ochsner J. 2023 Winter;23(4):315-328. doi: 10.31486/toj.23.0076. PMID: 38143548; PMCID: PMC10741816. 27. Fuentes JJ, Fonseca F, Elices M, et al. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Front Psychiatry. 2020 Jan 21;10:943. doi: 10.3389/fpsyt.2019.00943. PMID: 32038315; PMCID: PMC6985449. 28. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023 Jun;23(6):535-548. doi: 10.1080/14737175.2023.2211767. Epub 2023 May 15. PMID: 37183813. 29. Parikh TK, Strawn JR, Walkup JT, et al. Repetitive Transcranial Magnetic Stimulation for Generalized Anxiety Disorder: A Systematic Literature Review and Meta-Analysis. Int J Neuropsychopharmacol. 2022 Feb 11;25(2):144-146. doi: 10.1093/ijnp/pyab077. 30. Qi L, Wang S, Li X, et al. Non-invasive brain stimulation in the treatment of generalized anxiety disorder: A systematic review and meta-analysis. J Psychiatr Res. 2024 Oct;178:378-387. doi: 10.1016/j.jpsychires.2024. 07. 046. Epub 2024 Jul 31. 31. Covin R, Ouimet AJ, Seeds PM, et al. A meta-analysis of CBT for pathological worry among clients with GAD. Journal of anxiety disorders. 2008;22(1):108-116. 32. Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81(3):250-259. doi:10.1001/jamapsychiatry.2023.3971. 33. Grieger F, Klapperich H, Hassenzahl M. Trash It, Punch It, Burn It– Using Virtual Reality to Support Coping with Negative Thoughts. In Extended Abstracts of the 2021 CHI Conference on Human Factors in Computing Systems (s.1-6). Yokohama, Japan. 2021. doi.org/10.1145/3411763.3451738 34. Prudenzi A, Rooney B, Presti G, et al. Testing the effectiveness of virtual reality as a defusion technique for coping with unwanted thoughts. Virtual Reality. 2019;23(2): 179-185. doi.org/10.1007/s10055-018-0372-1. 35. Larsson A, Hooper N, Osborne LA, et al. Using brief cognitive restructuring and cognitive defusion techniques to cope with negative thoughts. Behavior Modification. 2016;40(3):452-482. doi.org/10.1177/0145445515621488. 36. Borkovec TD, Wilkinson L, Folensbee R, et al. Stimulus control applications to the treatment of worry. Behaviour research and therapy. 1983;21(3):247-251. doi.org/10.1016/00057967(83)90206-1. 37. Szkodny LE, Newman MG, Goldfried MR. Clinical experiences in conducting empirically supported treatments for generalized anxiety disorder. Behavior Therapy. 2014; 45(1): 7-20. doi.org/10.1016/j.beth.2013. 09. 009. 38. Dippel A, Brosschot JF, Verkuil B. Effects of worry postponement on daily worry: a meta-analysis. Preprints. 2022. doi. org/10.31219/osf.io/qkvhu. 39. Williams M, Honan C, Skromanis S, et al. Psychological outcomes and mechanisms of mindfulness-based training for generalised anxiety disorder: A systematic review and meta-analysis. Current Psychology. 2024;43(6):5318-5340. 40. Andoni M, Vaida S. Treatment of Generalized Anxiety Disorder with Virtual Reality. Systematic Review. Educatia. 2024;21(29). 41. Eilert N, Enrique A, Wogan R, et al. The effectiveness of Internet-delivered treatment for generalized anxiety disorder: An updated systematic review and meta-analysis. Depression and Anxiety. 2021;38(2):196-219. 42. Saramago P, Gega L, Marshall D, et al. Digital interventions for generalized anxiety disorder (GAD): systematic review and network meta-analysis. Frontiers in psychiatry. 2021;12:726222. 43. Dugas MJ, Freeston MH, Ladouceur R, et al. Worry themes in primary GAD, secondary GAD, and other anxiety disorders. J Anxiety Disord. 1998 May-Jun;12(3):253-61. doi: 10.1016/ s0887-6185(98)00013-9. 44. Donnelly MR, Reinberg R, Ito KL, et al. Virtual Reality for
RkJQdWJsaXNoZXIy NDA4Mjc=